<DOC>
	<DOCNO>NCT00749866</DOCNO>
	<brief_summary>The hypothesis randomize placebo control trial target nebulized gentamicin airway reduce bacterial burden limit neutrophil airways inflammation . If give long term improve symptom , pulmonary physiology , exercise capacity health relate quality life reduction exacerbation frequency health care utilization .</brief_summary>
	<brief_title>Long Term Nebulised Gentamicin Patients With Bronchiectasis</brief_title>
	<detailed_description />
	<mesh_term>Bronchiectasis</mesh_term>
	<mesh_term>Gentamicins</mesh_term>
	<criteria>Bronchiectasis confirm HRCT chest Clinically stable ( require antibiotic least 4 week precede study start date ) Aged 1870 Chronic sputum production &gt; 5 mls majority day 3 month enrolment Chronically colonize ( least 2 occasion precede 12 month ) whilst clinically stable At least two exacerbation past year Patients able tolerate nebulized gentamicin challenge FEV1 &gt; 30 % predict Smoking &lt; 20 pack year history exsmokers &gt; 1 year . Cystic fibrosis Emphysema HRCT chest Thoracic surgery within past 1 year Allergic bronchopulmonary aspergillosis Poorly control asthma ( &gt; 20 % diurnal variation peak expiratory flow despite treatment ) Unstable angina uncontrolled congestive cardiac failure Active malignancy Pregnancy breast feed Creatinine clearance &lt; 30 mls/minute Vestibular instability Previous document intolerance aminoglycosides</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>Nebulised antibiotic</keyword>
	<keyword>Non cystic fibrosis bronchiectasis</keyword>
	<keyword>Bacterial Load</keyword>
	<keyword>Inflammation</keyword>
	<keyword>Quality Life</keyword>
	<keyword>Side Effects</keyword>
</DOC>